Narocin

/ Teva

Adults: 1 tablet every 12 hours or a starting dose of 2 tablets a day. Do not exceed 2 tablets in 24 hours.
Elderly over 65 years old: Not more than 1.5 tablet in 24 hours.
See package insert (OTC).

Primary dysmenorrhea.

Hypersensitivity. Patients in whom aspirin or other NSAIDs induce serious allergic manifestations. Suppositories are contraindicated in patients with a history of proctitis or recent rectal bleeding. Active peptic ulcer.
See package insert (OTC).

Risk of GI ulceration, bleeding and perforation. Patients on prolonged corticosteroid therapy should have their therapy tapered slowly if a decision is made to discontinue corticosteroids. Should not be administered to patients with aspirin sensitivity, use with caution in patients with pre-existing asthma. History of gastrointestinal disease, elderly and debilitated patients, liver dysfunction. Abnormal liver test has been reported. Pregnancy and lactation. Patients with initial hemoglobin values of 10g or less who are to receive long-term therapy should have hemoglobin values determined frequently. Patients with compromised cardiac function. Ability to perform potentially-hazardous tasks may be impaired. Ophthalmological studies should be carried out within a reasonable period of time after starting naproxen therapy and repeated at periodic intervals if the drug is to be used for an extended period of time. Patients who have coagulation disorders or on full anticoagulation therapy, may be at increased risk of bleeding if given naproxen concurrently, impaired renal function, impaired hepatic function.
See package insert (OTC).

Dizziness, abdominal pain, diarrhea, dyspepsia, flatulence.
See package insert (OTC).